Jazz Pharmaceuticals (JAZZ) – Hot FDA News
-
Jazz Pharmaceuticals (JAZZ) Declined 4% After Phase 2 Trial of JZP150 in PTSD Fails
-
Jazz Pharmaceuticals (JAZZ), Zymeworks (ZYME) Announce 84% OS at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
-
-
-
-
-
-
-
-
-
-
-
-
Back to JAZZ Stock Lookup